TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24946626

Group type: EXPERIMENTAL
Intervention: Moxibustion applied to Zusanli (ST 36) and Sanyinjiao (SP 6), 2-3 times a day for 4 weeks, 3 sessions total.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment continued for 3 months follow-up.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment before and after treatment comparison.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group received regular hemodialysis and conventional medication without moxibustion.
Number of subjects: 109
Study: 23058854

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ketorolac tromethamine in 1 L of normal saline
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 20643988

Group type: EXPERIMENTAL
Intervention: Probing for contextual red flags
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Probing for biomedical red flags
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in uncomplicated encounters
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in biomedically complicated encounters
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in contextually complicated encounters
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Error-free treatment plans in combined biomedically and contextually complicated encounters
Number of subjects: 111
Study: 17684777

Group type: EXPERIMENTAL
Intervention: Dynamic plate (ABC, Aesculap, Germany)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Rigid plate (CSLP, Synthes, Switzerland)
Number of subjects: 132
Study: 16236834

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 20
Study: 15571441

Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.0 g/kg (placebo)
Number of subjects: 10
Study: 10726009

Group type: EXPERIMENTAL
Intervention: Aprosulate 0.5 mg/kg body weight
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aprosulate 1.0 mg/kg body weight
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unfractionated heparin (Calciparin 7,500 IU)
Number of subjects: 18
Study: 7734259

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1 i.v. pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium without magnesium pretreatment
Number of subjects: 0
Study: 2203304

Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin given concurrently to normal volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin given concurrently to anuric patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime and tobramycin given separately
Number of subjects: 0
Study: 7038839

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (PGE2), 0.33 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15(R)15 Me PGE2, 40 micrograms three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin, 50 mg three times daily
Number of subjects: 0
Study: 28440549

Group type: EXPERIMENTAL
Intervention: U.S. cable TV consumption
Number of subjects: 330
Study: 26946614

Group type: EXPERIMENTAL
Intervention: Acupuncture-movement therapy (AM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture (CA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture-movement therapy (SAM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 60
Study: 25203651

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lemon tea (LT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 19
Study: 22765882

Group type: EXPERIMENTAL
Intervention: Provider education and access to a CKD registry
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control clinic (education only)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Control and intervention clinics
Number of subjects: 418
Study: 20658390

Group type: EXPERIMENTAL
Intervention: Traffic noise conditions (even, lumped) with 20%, 40% heavy vehicles
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High noise sensitivity
Number of subjects: 102
Study: 17980202

Group type: EXPERIMENTAL
Intervention: Surgical simulator laboratory on laparoscopic tubal ligation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Apprenticeship teaching alone
Number of subjects: 20
Study: 16327260

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 0
Study: 12135710

Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with routine mesh repair
Number of subjects: 4688

Group type: COMPARATOR
Intervention: Open hernia repair (OHR) with mesh
Number of subjects: 4688

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR)
Number of subjects: 4688
Study: 9689830

Group type: EXPERIMENTAL
Intervention: Routine coronary angiogram (CAG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Risk factors for CAD (smoking, hypertension, hypercholesterolemia, diabetes)
Number of subjects: 50
Study: 7989943

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for patients with measurable disease
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for patients with assessable disease
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Survival of responders only
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Assessable disease
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 426
Study: 2692375

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 29575386

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 189
Study: 26699231

Group type: EXPERIMENTAL
Intervention: Active Teen Leaders Avoiding Screen‐time (ATLAS) intervention
Number of subjects: 361
Study: 25156082

Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled drugs or vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% terbinafine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% bifonazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% or 0.5% luliconazole
Number of subjects: 0
Study: 22490808

Group type: EXPERIMENTAL
Intervention: Step-up infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Top-down infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Step-up infliximab therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Top-down infliximab therapy
Number of subjects: 41
Study: 20381933

Group type: COMPARATOR
Intervention: Nut consumption <1 time/week
Number of subjects: 21078

Group type: COMPARATOR
Intervention: Nut consumption 1 time/week
Number of subjects: 21078

Group type: COMPARATOR
Intervention: Nut consumption 2-4 times/week
Number of subjects: 21078

Group type: COMPARATOR
Intervention: Nut consumption 5-6 times/week
Number of subjects: 21078

Group type: COMPARATOR
Intervention: Nut consumption ≥7 times/week
Number of subjects: 21078
Study: 18441453

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 45
Study: 15842582

Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vitamin E (800 IU/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prescriptive weight-reducing diet
Number of subjects: 110
Study: 14562993

Group type: EXPERIMENTAL
Intervention: Nutritional calcium intake (Ca)
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 937
Study: 10817000

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1 MAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.5 MAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2 MAC
Number of subjects: 80

Group type: COMPARATOR
Intervention: TIVA with fentanyl and propofol
Number of subjects: 80
Study: 9133197

Group type: EXPERIMENTAL
Intervention: alfentanil 15 mu g/kg
Number of subjects: 119

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: alfentanil 30 mu g/kg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg/kg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: alfentanil 15 mu g/kg and alfentanil 30 mu g/kg
Number of subjects: 119
Study: 8213541

Group type: EXPERIMENTAL
Intervention: 5 mg IS-5-MN
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 10 mg IS-5-MN
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 20 mg IS-5-MN
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 2890369

Group type: EXPERIMENTAL
Intervention: 10 mg etretin daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 25 mg etretin daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 mg etretin daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29777950

Group type: EXPERIMENTAL
Intervention: TAU plus a 1-day ACT workshop (n=44)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=44)
Number of subjects: 88
Study: 27297519

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% (w/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (w/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 10% (w/w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine (all doses)
Number of subjects: 0
Study: 24729537

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (health education videos)
Number of subjects: 99
Study: 24280467

Group type: EXPERIMENTAL
Intervention: Magnetotherapy (25Hz, 450 pulse/s, 5‐80G, 20 min/day for 10 days)
Number of subjects: 50
Study: 22378291

Group type: COMPARATOR
Intervention: High saturated fatty acids diet
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acids diet
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 466
Study: 19250161

Group type: EXPERIMENTAL
Intervention: LHA formulation (twice a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Benzoyl peroxide (5%, once a day)
Number of subjects: 80
Study: 16707816

Group type: EXPERIMENTAL
Intervention: Disulfiram and low nickel diet (LND) for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (lactose tablet) with normal diet for 4 weeks
Number of subjects: 21
Study: 15106392

Group type: EXPERIMENTAL
Intervention: Robotic cat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plush toy cat
Number of subjects: 0
Study: 11297958

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (probiotic)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 8909512

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open splenectomy
Number of subjects: 20
Study: 1918562

Group type: EXPERIMENTAL
Intervention: More frequent empathic responses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Suggestions volunteered by therapists
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Asking questions by therapists
Number of subjects: 6
Study: 6132085

Group type: EXPERIMENTAL
Intervention: Neurotensin 13.5 pmol kg‐1 min‐1 for 30 min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control infusions
Number of subjects: 5
Study: 30590759

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28238195

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (5 loading doses every 4 weeks until week 16, then extended to 8 weeks)
Number of subjects: 43
Study: 26554774

Group type: EXPERIMENTAL
Intervention: Enteral feeding (EN) group, n = 17
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (intravenous fluid until oral diets initiated), n = 19
Number of subjects: 36
Study: 23259717

Group type: EXPERIMENTAL
Intervention: Compensation group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Restitution group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Compensation and restitution groups
Number of subjects: 11

Group type: COMPARATOR
Intervention: Self-help group
Number of subjects: 11
Study: 21881151

Group type: EXPERIMENTAL
Intervention: Optimized braking force (8.5%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard braking force (4.5%)
Number of subjects: 8
Study: 19562622

Group type: EXPERIMENTAL
Intervention: Fasting preparation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-fasting preparation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fasting preparation (in male patients)
Number of subjects: 143
Study: 17591658

Group type: EXPERIMENTAL
Intervention: S-ketamine (moderate and high doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: N,N-dimethyltryptamine (DMT) (moderate and high doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 15
Study: 15553604

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining total knee arthroplasty (CR TKA)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Cruciate-substituting total knee arthroplasty (CS TKA)
Number of subjects: 228
Study: 11605747

Group type: EXPERIMENTAL
Intervention: Hip protectors worn throughout the whole 10 months
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Hip protectors with initial wearing period
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Hip protectors refused to wear
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Regular wearers of hip protectors
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Drop-outs from wearing hip protectors
Number of subjects: 548
Study: 9444446

Group type: EXPERIMENTAL
Intervention: mibefradil 50 mg QD (titrated to 100 mg if needed)
Number of subjects: 296

Group type: COMPARATOR
Intervention: amlodipine 5 mg QD (titrated to 10 mg if needed)
Number of subjects: 296
Study: 7926302

Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 132
Study: 2735335

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g four times per day
Number of subjects: 26

Group type: COMPARATOR
Intervention: cimetidine 400 mg twice daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 26

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 26
Study: 4613534

Group type: EXPERIMENTAL
Intervention: Quingestanol acetate 800 mcg in Mexico
Number of subjects: 2702

Group type: EXPERIMENTAL
Intervention: Quingestanol acetate 750 mcg in Chile and Peru
Number of subjects: 2702
Study: 30428396

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 28260598

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (weekly for five consecutive weeks at predefined acupuncture points: CV-3, CV-4, LR-8, SP-6, SP-9)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (late acupuncture)
Number of subjects: 68
Study: 26204135

Group type: EXPERIMENTAL
Intervention: Algorithmic adjusted basal rate and carbohydrate ratio settings
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unchanged (control) settings
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both arms of CLC
Number of subjects: 37
Study: 24136731

Group type: EXPERIMENTAL
Intervention: ARA 290 (daily subcutaneous administration for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARA 290
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21288841

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (12-week course of clarithromycin and rifabutin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 50
Study: 19614943

Group type: EXPERIMENTAL
Intervention: Enhanced Lifestyle Programme (ELP) targeting walking speed
Number of subjects: 41

Group type: COMPARATOR
Intervention: Basic Lifestyle Programme (BLP) targeting total daily steps
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both ELP and BLP
Number of subjects: 41
Study: 16861090

Group type: EXPERIMENTAL
Intervention: Glimepiride + Pioglitazone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Glimepiride + Rosiglitazone
Number of subjects: 91
Study: 14629093

Group type: EXPERIMENTAL
Intervention: Count to 10 chart
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hollister chart
Number of subjects: 40
Study: 10867599

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) via novel multidose dry-powder inhaler (DPI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) via conventional pressurised metered-dose inhaler (pMDI) with spacer
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments (DPI and pMDI)
Number of subjects: 27
Study: 9085300

Group type: EXPERIMENTAL
Intervention: Group 1 (non-pregnant awaiting tubal ligation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2 (non-pregnant with acute postoperative pain)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3 (pregnant awaiting elective cesarean section)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 4 (pregnant in active labor)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pregnant groups (groups 3 and 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acute postoperative pain or labor pain
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study: 8412394

Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 185
Study: 3531220

Group type: EXPERIMENTAL
Intervention: Naloxone (NLX; 0.08 mg/kg BW, iv)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GnRH (50 micrograms, iv)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29135692

Group type: EXPERIMENTAL
Intervention: Combined ultrasonography-neurostimulation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ultrasound guidance alone
Number of subjects: 110
Study: 27170565

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 288
Study: 24421075

Group type: EXPERIMENTAL
Intervention: Feedback-based alcohol intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback about other health-related behaviors (control condition)
Number of subjects: 0
Study: 22537732

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy insomnia intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional depression-focused treatment
Number of subjects: 0
Study: 20124143

Group type: EXPERIMENTAL
Intervention: Intervention program targeting physical activity injuries
Number of subjects: 2210

Group type: COMPARATOR
Intervention: Regular curriculum (Control)
Number of subjects: 2210
Study: 17651144

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 630

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: GSTT1 and GSTM1 null genotypes
Number of subjects: 630
Study: 16171419

Group type: EXPERIMENTAL
Intervention: 4-factor representation of dispositional appraisal
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-factor representation of dispositional appraisal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-factor solution
Number of subjects: 0
Study: 12234860

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg daily for 30 days
Number of subjects: 5
Study: 10424293

Group type: EXPERIMENTAL
Intervention: Training sample (n=506)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Test sample (n=255)
Number of subjects: 761
Study: 7478808

Group type: EXPERIMENTAL
Intervention: Pubertal development graded into three groups according to estradiol and testosterone concentrations
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Prepubertal children
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Linear correlation between IGF‐I and IGFBP‐3
Number of subjects: 354
Study: 2126396

Group type: EXPERIMENTAL
Intervention: Sustac (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trinitrolong (TNL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term continuous treatment with ST and TNL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term continuous treatment with ST
Number of subjects: 0
Study: 91889

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone (intervention)
Number of subjects: 20
Study: 30088217

Group type: EXPERIMENTAL
Intervention: RLIC
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 69
Study: 28068912

Group type: EXPERIMENTAL
Intervention: Soap-and-water hand wash
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1270